These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 18191967

  • 1. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC, Popeijus HE.
    Physiol Behav; 2008 May 23; 94(2):187-97. PubMed ID: 18191967
    [Abstract] [Full Text] [Related]

  • 2. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.
    Pharmacol Rev; 2006 Dec 23; 58(4):726-41. PubMed ID: 17132851
    [Abstract] [Full Text] [Related]

  • 3. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb 23; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C, Tsantili-Kakoulidou A, Theocharis S.
    Fundam Clin Pharmacol; 2007 Jun 23; 21(3):231-44. PubMed ID: 17521292
    [Abstract] [Full Text] [Related]

  • 5. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB, Lichnovská R, Brychta T.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec 23; 149(2):237-41. PubMed ID: 16601762
    [Abstract] [Full Text] [Related]

  • 6. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J.
    J Intern Med; 2007 Aug 23; 262(2):184-98. PubMed ID: 17645586
    [Abstract] [Full Text] [Related]

  • 7. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G, Torres N, Tovar AR.
    Rev Invest Clin; 2004 Aug 23; 56(3):351-67. PubMed ID: 15612519
    [Abstract] [Full Text] [Related]

  • 8. Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment?
    Grimaldi PA.
    Biochimie; 2005 Jan 23; 87(1):5-8. PubMed ID: 15733729
    [Abstract] [Full Text] [Related]

  • 9. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
    Fernandez AZ.
    Curr Opin Investig Drugs; 2004 Sep 23; 5(9):936-40. PubMed ID: 15503647
    [Abstract] [Full Text] [Related]

  • 10. PPARs and the kidney in metabolic syndrome.
    Ruan X, Zheng F, Guan Y.
    Am J Physiol Renal Physiol; 2008 May 23; 294(5):F1032-47. PubMed ID: 18234957
    [Abstract] [Full Text] [Related]

  • 11. PPARs: molecular targets in the pharmacogenomics era.
    Seda O, Sedová L.
    Prague Med Rep; 2004 May 23; 105(3):223-36. PubMed ID: 15782550
    [Abstract] [Full Text] [Related]

  • 12. [Nuclear Receptor PPARs and magnesium].
    Fujii H.
    Clin Calcium; 2005 Nov 23; 15(11):52-64. PubMed ID: 16272614
    [Abstract] [Full Text] [Related]

  • 13. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
    Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich A, Grimaldi PA.
    Biochimie; 2004 Nov 23; 86(11):833-7. PubMed ID: 15589693
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA, Piqueras L, Bishop-Bailey D.
    Pharmacol Ther; 2006 Jun 23; 110(3):371-85. PubMed ID: 16168490
    [Abstract] [Full Text] [Related]

  • 15. PPAR agonists and the metabolic syndrome.
    Staels B.
    Therapie; 2007 Jun 23; 62(4):319-26. PubMed ID: 17983557
    [Abstract] [Full Text] [Related]

  • 16. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD, Plutzky J.
    Circulation; 2007 Jan 30; 115(4):518-33. PubMed ID: 17261671
    [Abstract] [Full Text] [Related]

  • 17. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA, Sylte I.
    J Mol Graph Model; 2008 Sep 30; 27(2):217-24. PubMed ID: 18547851
    [Abstract] [Full Text] [Related]

  • 18. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD.
    Ann N Y Acad Sci; 2006 Nov 30; 1083():306-18. PubMed ID: 17148746
    [Abstract] [Full Text] [Related]

  • 19. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y.
    J Am Soc Nephrol; 2004 Nov 30; 15(11):2801-15. PubMed ID: 15504933
    [Abstract] [Full Text] [Related]

  • 20. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M.
    Prog Mol Biol Transl Sci; 2014 Nov 30; 121():217-66. PubMed ID: 24373239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.